A study has been published in The Spine Journal that summarizes the results of preclinical testing for Discogenic Cells, the active ingredient in IDCT, DiscGenics’ investigational cell therapy for disc degeneration.
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DiscGenics’ investigational cell therapy, IDCT, currently being evaluated in regulator-allowed clinical trials in the U.S. and Japan for the reduction in pain and disability associated with degenerative disc disease (DDD), a major cause of chronic low back pain.
The first Utahns have been treated in DiscGenics' nationwide clinical study of IDCT, a locally developed injectable disc cell therapy for degenerative disc disease (DDD).
Chief Medical Officer, Kevin T. Foley, MD, FACS, FAANS was awarded the 2019 AANS Cushing Award for Technical Excellence and Innovation in Neurosurgery. The award honors an AANS member for technical prowess and skill and/or innovation in the development of new procedures that have become part of the arsenal a neurosurgeon uses to treat disease or trauma.
IDCT has passed the initial planned safety review of a Phase I/II trial evaluating the allogeneic, injectable disc cell therapy in patients with mild to moderate degenerative disc disease.
The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved DiscGenics' Clinical Trial Notification (CTN) application for IDCT, an allogeneic injectable disc cell therapy for the treatment of degenerative disc disease (DDD) in Japan.
Flagg Flanagan, Chairman and CEO of DiscGenics, will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa, on Wednesday, October 3, 2018 at 4:15pm PDT in La Jolla, CA.
DiscGenics has engaged with CCRM and GE Healthcare, leaders in developing and commercializing cell and gene therapy technologies, to support the Company’s efforts to scale and optimize manufacturing of its homologous, allogeneic (off-the- shelf), injectable cell therapy.
CTI Clinical Trial and Consulting Services (CTI) announces its collaboration with DiscGenics on the execution of a first-in-human trial of IDCT for degenerative disc disease (DDD).
DiscGenics, Inc. presented results from two preclinical studies of IDCT at the Orthopedic Research Society (ORS) 2018 Annual Meeting, which was held last week in New Orleans, LA.
DiscGenics has selected Cryoport to provide logistics support to its multicenter, first-in-human study to evaluate the safety and preliminary efficacy of IDCT in patients with single level, symptomatic lumbar intervertebral disc degeneration.
MedCision, LLC, the world leader in next-generation automated cell thawing for advanced therapies, and DiscGenics, Inc., a regenerative medicine company focused on developing cell therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that DiscGenics has joined MedCision’s ThawSTAR Clinical Early Adopter Program.
DiscGenics, Inc., a clinical stage regenerative medicine company focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, is pleased to announce that it has been notified by the U.S. Food and Drug Administration (FDA) that an Investigational New Drug (IND) Application for a clinical study of its first product candidate, IDCT, may proceed.
DiscGenics, Inc., a clinical stage regenerative medicine company focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced it has closed a $14 million Series B financing.
DiscGenics, Inc. (DiscGenics) announces the allowance of 9 additional patents that expand its intellectual property portfolio within both the U.S. and globally to 24 issued patents. The new patents include 2 in the U.S. and 7 in key European markets.
DiscGenics, Inc. (DiscGenics) announces that the company has been selected as a Global Innovations Partner by Cavendish Global.